HK Stock Market Move | HANSOH PHARMA (03692) rose nearly 3% in midday trading, the company and other pharmaceutical companies jointly applied for the listing of a new indication for the anti-CD19 monoclonal antibody.

HANSOH PHARMA (03692) rose nearly 3% during the trading day, as of the time of reporting, it had risen 2.35% to HK $18.3, with a turnover of HK $60.43 million. On the news front, on March 4th, according to the official website of the Drug Evaluation Center of the China National Medical Products Administration, a new indication market approval application for Inzelenzumab monoclonal antibody injection jointly declared by Horizon Therapeutics, Astrazeneca PLC Sponsored ADR (AZN.US), and HANSOH PHARMA (03692) has been accepted for review. Inzelenzumab monoclonal antibody is an anti-CD19 monoclonal antibody, which was formally included in the priority review by CDE in February this year for the treatment of adult patients with immunoglobulin G4-related diseases (IgG4-RD). Therefore, this may be the indication for which the product is applying for market approval this time. It is reported that Inzelenzumab monoclonal antibody is a targeted CD19 B cell-depleting antibody. In 2019, HANSOH PHARMA entered into a licensing agreement with Viela Bio to obtain the exclusive license for the development and commercialization of the product in mainland China, Hong Kong, and Macau (Viela Bio was acquired by Horizon Therapeutics in 2021, which was acquired by AbbVie in 2023). Inzelenzumab monoclonal antibody has been approved for market in the United States and China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for aquaporin 4 (AQP4) antibodies.